RecruitingPHASE1, PHASE2NCT05288205
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allist Pharmaceuticals, Inc.
- Principal Investigator
- Wang Wang Jie M.D.Peking University Cancer Hospital & Institute
- Intervention
- JAB-21822(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (27)
- The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
- Pecking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing Municipality, China
- Beijing Tiantan Hospital, Captal Medical University, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Beijing Chest Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- Fujian cancer Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital Xiamen University, Xiamen, Fujian, China
- The first Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Zhujiang Hospital of Southem Medical University, Guangzhou, Guangdong, China
- Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center, Shenzhen, Guangdong, China
- Harbin Medical University Cancer Hospital-Mammary gland of internal, Harbin, Heilongjiang, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- The First Affiliated Hosipital Of Zhengzhou University, Zhengzhou, Henan, China
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05288205 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital